Holen Sie sich die Stockscreener-App
1.32
15.79%
0.18
Handel nachbörslich:
1.30
-0.02
-1.52%
Schlusskurs vom Vortag:
$1.14
Offen:
$1.12
24-Stunden-Volumen:
840.61K
Relative Volume:
1.70
Marktkapitalisierung:
$124.15M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-3.4847
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
+11.86%
1M Leistung:
-20.00%
6M Leistung:
-67.41%
1J Leistung:
-33.67%
1-Tages-Spanne:
$1.12
$1.39
1-Wochen-Bereich:
$1.10
$1.39
52-Wochen-Spanne:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.32 | 124.15M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Affinity Asset Advisors LLC Makes New Investment in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
575,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Altium Capital Management LLC - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of “Buy” by Brokerages - Defense World
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com
ProQR (PRQR) Strengthens Leadership with New CFO and CMO Appointments | PRQR Stock News - GuruFocus
ProQR Strengthens Leadership with Appointments of CFO and CMO to - GuruFocus
ProQR names new CFO and CMO to bolster RNA editing platform By Investing.com - Investing.com South Africa
ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 34% - simplywall.st
ProQR names new CFO and CMO to bolster RNA editing platform - Investing.com Canada
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth - GlobeNewswire
ProQR strengthens leadership team - The Pharma Letter
ProQR Therapeutics CFO Jurriaan Dekkers Steps Down, Dennis Hom To Succeed; Cristina Lopez Named CMO - Nasdaq
American Century Companies Inc. Invests $237,000 in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by Prudential Financial Inc. - Defense World
Raymond James Financial Inc. Acquires Shares of 97,928 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Virtu Financial LLC Buys New Stake in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Chardan Capital Issues Optimistic Forecast for PRQR Earnings - MarketBeat
FY2025 EPS Estimate for ProQR Therapeutics Lifted by Analyst - Defense World
28,903 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by PNC Financial Services Group Inc. - Defense World
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Price Target at $9.50 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives $9.50 Average Target Price from Analysts - The AM Reporter
Privium Fund Management B.V. Sells 646,755 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Platinum Investment Management Ltd. Makes New $4.08 Million Investment in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of “Buy” by Brokerages - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Chardan Capital - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for ProQR Therapeutics (NASDAQ:PRQR) Stock - MarketBeat
H.C. Wainwright raises ProQR stock target to $12, maintains Buy By Investing.com - Investing.com Australia
H.C. Wainwright raises ProQR stock target to $12, maintains Buy - Investing.com India
ProQR Therapeutics (NASDAQ:PRQR) Issues Quarterly Earnings Results - MarketBeat
Chardan Capital Reaffirms Buy Rating for ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Raymond James maintains Strong Buy on ProQR stock, $14 target By Investing.com - Investing.com Australia
Raymond James maintains Strong Buy on ProQR stock, $14 target - Investing.com India
ProQR Therapeutics NV earnings beat, revenue fell short of estimates - Investing.com
ProQR Therapeutics NV earnings beat, revenue fell short of estimates By Investing.com - Investing.com South Africa
Proqr Therapeutics NV Files For Shelf Of Up To Up To 3.5 Million Ordinary Shares By Selling StockholderSEC Filing - Marketscreener.com
SEC Form 20-F filed by ProQR Therapeutics N.V. - Quantisnow
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):